(NASDAQ: COLL) Collegium Pharmaceutical's forecast annual revenue growth rate of 0.67% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.93%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.79%.
Collegium Pharmaceutical's revenue in 2025 is $664,283,000.On average, 3 Wall Street analysts forecast COLL's revenue for 2025 to be $24,211,620,399, with the lowest COLL revenue forecast at $24,180,571,042, and the highest COLL revenue forecast at $24,267,354,960. On average, 3 Wall Street analysts forecast COLL's revenue for 2026 to be $24,875,260,237, with the lowest COLL revenue forecast at $24,154,857,288, and the highest COLL revenue forecast at $25,356,975,269.
In 2027, COLL is forecast to generate $20,652,965,470 in revenue, with the lowest revenue forecast at $19,008,892,349 and the highest revenue forecast at $22,297,038,590.